NCT05941741 2026-03-18
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Sun Yat-sen University
Phase 3 Recruiting
Clinical Trials
201 trialsNCT07359040 2026-03-12
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
Peking University People's Hospital
Active not recruiting
NCT07466225 2026-03-12
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion
Peking University
Not yet recruiting
NCT07466238 2026-03-12
HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
Peking University
Not yet recruiting
NCT07468630 2026-03-12
TRIUNITE-08
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Recruiting
NCT03313804 2026-03-11
Priming Immunotherapy in Advanced Disease With Radiation
University of Kentucky
Phase 2 Completed
NCT07457099 2026-03-09
Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
Zhujiang Hospital
Not yet recruiting
NCT06647680 2026-03-06
Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）
The Affiliated Hospital of Qingdao University
Phase 2 Recruiting
NCT07453342 2026-03-06
Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge
Peking Union Medical College Hospital
Recruiting
NCT06502691 2026-03-02
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
University of Washington
Phase 1/2 Recruiting
NCT04290546 2026-02-27
CIML NK Cell in Head & Neck Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT07110103 2026-02-27
JACKPOT38
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
NCT06802757 2026-02-25
PRISM-TNBC
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT07427186 2026-02-25
MINER2
Institut Claudius Regaud
Phase NA Not yet recruiting
NCT07428252 2026-02-25
Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma
Institute of Oncology Ljubljana
Phase NA Active not recruiting
NCT07432568 2026-02-25
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07434518 2026-02-25
A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Recruiting
NCT03514368 2026-02-19
MINER
Institut Claudius Regaud
Phase NA Recruiting
NCT04913311 2026-02-19
Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Recruiting
NCT06524570 2026-02-18
iFOCUS
UMC Utrecht
Phase 1 Recruiting
NCT07417501 2026-02-18
Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification
Tongji Hospital
Phase 2 Not yet recruiting
NCT07405086 2026-02-12
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT06964568 2026-02-10
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
Fudan University
Phase 3 Recruiting
NCT06610734 2026-02-09
SKY
Sichuan University
Phase 2 Recruiting
NCT05358938 2026-02-06
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT07389876 2026-02-05
G/GEJ
Fudan University
Recruiting
NCT07385989 2026-02-04
Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06627712 2026-01-30
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
West China Hospital
Phase 3 Recruiting
NCT06283238 2026-01-29
Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)
Duke University
Withdrawn
NCT05166239 2026-01-23
HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT
Peking University
Phase 2 Completed
NCT07363369 2026-01-23
Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors
West China Hospital
Phase 1 Not yet recruiting
NCT07364305 2026-01-23
Lalo
Eastern Hepatobiliary Surgery Hospital
Phase 2 Recruiting
NCT04995003 2026-01-22
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Baylor College of Medicine
Phase 1 Recruiting
NCT07339488 2026-01-14
ILDR-03
Shantou University Medical College
Phase 2 Active not recruiting
NCT07327411 2026-01-08
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT07317778 2026-01-05
Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT07230639 2025-12-26
MODIFI-CC
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Recruiting
NCT07279077 2025-12-26
MODIFI-L
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Recruiting
NCT07282184 2025-12-18
Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
Tongji Hospital
Phase 1/2 Recruiting
NCT05013450 2025-12-17
Dupilumab_Metastatic NSCLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Active not recruiting
NCT06349837 2025-12-17
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
Sichuan University
Phase 1 Recruiting
NCT07285395 2025-12-16
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
The Affiliated Hospital of Xuzhou Medical University
Phase 1 Recruiting
NCT07282262 2025-12-15
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT07271602 2025-12-09
A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT07249060 2025-12-03
INTER-AUTENTIC
Hospital Universitario Araba
Recruiting
NCT05440916 2025-12-02
PRIMM
University Medical Centre Maribor
Phase 2 Completed
NCT06248554 2025-12-02
Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation
Tongji Hospital
Phase NA Recruiting
NCT06154538 2025-11-28
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT07238569 2025-11-20
Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting